Progress Toward Oral Therapy for Celiac Disease

abbvie

The world’s leading health organizations supporting celiac disease awareness and education (Celiac Disease Foundation, American Celiac Disease Alliance, Celiac Sprue Association, Gluten Intolerance Group and the National Foundation for Celiac Awareness) applaud the efforts of Alvine Pharmaceuticals and AbbVie in addressing the significant unmet medical need for therapeutic treatment of celiac disease. ALV003 is an investigational oral therapy composed of two recombinant, gluten specific enzymes (a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP)), that degrade gluten in-vitro and in human clinical testing, and may reduce the symptoms and intestinal injury associated with celiac disease in patients attempting to adhere to a gluten-free diet.

Read article